GLP-1 analog attenuates cocaine reward. Graham DL, Erreger K, Galli A, Stanwood GD (2013) Mol Psychiatry 18: 961-2 Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells. Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't Veld P, Saada A, Magnuson MA, Glaser B, Dor Y (2014) Cell Metab 19: 109-21 The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. Panaro BL, Tough IR, Engelstoft MS, Matthews RT, Digby GJ, Møller CL, Svendsen B, Gribble F, Reimann F, Holst JJ, Holst B, Schwartz TW, Cox HM, Cone RD (2014) Cell Metab 20: 1018-29 Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery. Albaugh VL, Banan B, Antoun J, Xiong Y, Guo Y, Ping J, Alikhan M, Clements BA, Abumrad NN, Flynn CR (2019) Gastroenterology 156: 1041-1051.e4 Age-dependent human β cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. Dai C, Hang Y, Shostak A, Poffenberger G, Hart N, Prasad N, Phillips N, Levy SE, Greiner DL, Shultz LD, Bottino R, Kim SK, Powers AC (2017) J Clin Invest 127: 3835-3844 Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT, Zhou W, Newcomb DC, Ware LB, Stanwood GD, Galli A, Boyd KL, Niswender KD, Peebles RS (2018) J Allergy Clin Immunol 142: 1515-1528.e8 Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, Nangaku M, Noiri E (2013) J Am Soc Nephrol 24: 2034-43 The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y, Yamada Y (2014) Kidney Int 85: 579-89 Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog. Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD (2009) Diabetes 58: 243-9 Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Hui H, Wright C, Perfetti R (2001) Diabetes 50: 785-96 The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice. Burmeister MA, Ayala JE, Smouse H, Landivar-Rocha A, Brown JD, Drucker DJ, Stoffers DA, Sandoval DA, Seeley RJ, Ayala JE (2017) Diabetes 66: 372-384 The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Isbell JM, Tamboli RA, Hansen EN, Saliba J, Dunn JP, Phillips SE, Marks-Shulman PA, Abumrad NN (2010) Diabetes Care 33: 1438-42 Gcg knockin mice as a tool for genetic manipulation in pancreatic alpha cells. Shiota C, Prasadan K, Guo P, Fusco J, Xiao X, Gittes GK (2017) Diabetologia 60: 2399-2408 Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). Morris LC, Nance KD, Gentry PR, Days EL, Weaver CD, Niswender CM, Thompson AD, Jones CK, Locuson CW, Morrison RD, Daniels JS, Niswender KD, Lindsley CW (2014) J Med Chem 57: 10192-7 Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L, NN8022-1923 Investigators (2013) Int J Obes (Lond) 37: 1443-51 Liraglutide increases islet Ca oscillation frequency and insulin secretion by activating hyperpolarization-activated cyclic nucleotide-gated channels. Zaborska KE, Jordan KL, Thorson AS, Dadi PK, Schaub CM, Nakhe AY, Dickerson MT, Lynch JC, Weiss AJ, Dobson JR, Jacobson DA (2022) Diabetes Obes Metab 24: 1741-1752 Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B (2013) Diabetes Obes Metab 15: 42-54 Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet. Ustione A, Piston DW, Harris PE (2013) Mol Endocrinol 27: 1198-207 Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis. Linnemann AK, Neuman JC, Battiola TJ, Wisinski JA, Kimple ME, Davis DB (2015) Mol Endocrinol 29: 978-87 Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, Cherrington AD (2003) Am J Physiol Endocrinol Metab 284: E1027-36 Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD (2007) Am J Physiol Endocrinol Metab 293: E1085-91 Jejunal administration of glucose enhances acyl ghrelin suppression in obese humans. Tamboli RA, Sidani RM, Garcia AE, Antoun J, Isbell JM, Albaugh VL, Abumrad NN (2016) Am J Physiol Endocrinol Metab 311: E252-9 Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD (2008) Am J Physiol Endocrinol Metab 294: E380-4 Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine. Doliba NM, Qin W, Vatamaniuk MZ, Li C, Zelent D, Najafi H, Buettger CW, Collins HW, Carr RD, Magnuson MA, Matschinsky FM (2004) Am J Physiol Endocrinol Metab 286: E834-43 Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD (2004) Am J Physiol Endocrinol Metab 287: E75-81 Effect of portal glucose sensing on incretin hormone secretion in a canine model. Edgerton DS, Kraft G, Smith MS, Moore LM, Farmer B, Scott M, Moore MC, Nauck MA, Cherrington AD (2019) Am J Physiol Endocrinol Metab 317: E244-E249 Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. Schwetz TA, Reissaus CA, Piston DW (2014) PLoS One 9: e113020 A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain. Graham DL, Durai HH, Trammell TS, Noble BL, Mortlock DP, Galli A, Stanwood GD (2020) J Comp Neurol 528: 2445-2470 Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Hansen EN, Tamboli RA, Isbell JM, Saliba J, Dunn JP, Marks-Shulman PA, Abumrad NN (2011) Am J Physiol Gastrointest Liver Physiol 300: G795-802 Exendin-4 decreases amphetamine-induced locomotor activity. Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD, Galli A (2012) Physiol Behav 106: 574-8 Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice. Lee EY, Kim YW, Oh H, Choi CS, Ahn JH, Lee BW, Kang ES, Cha BS, Lee HC (2014) Metabolism 63: 793-9 GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Smith NK, Hackett TA, Galli A, Flynn CR (2019) Neurochem Int 128: 94-105 Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward. Reddy IA, Stanwood GD, Galli A (2014) Neurochem Int 73: 49-55 Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog. Johnson KM, Farmer T, Schurr K, Patrick Donahue E, Farmer B, Neal D, Cherrington AD (2011) Endocrine 39: 229-34 A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors. Morris LC, Days EL, Turney M, Mi D, Lindsley CW, Weaver CD, Niswender KD (2014) J Biomol Screen 19: 847-58 Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor. Simmons JH, Shoemaker AH, Roth CL (2012) Horm Res Paediatr 78: 54-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.